24. Hepatitis C and Hepatocellular Carcinoma

  1. Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci2,
  2. Anna S.F. Lok MD3,
  3. Stephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath4 and
  4. Arie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci5
  1. Hubert E. Blum

Published Online: 26 JUL 2013

DOI: 10.1002/9781118637272.ch24

Viral Hepatitis, Fourth Edition

Viral Hepatitis, Fourth Edition

How to Cite

Blum, H. E. (2013) Hepatitis C and Hepatocellular Carcinoma, in Viral Hepatitis, Fourth Edition (eds H. C. Thomas, A. S.F. Lok, S. A. Locarnini and A. J. Zuckerman), John Wiley & Sons, Ltd, Oxford, UK. doi: 10.1002/9781118637272.ch24

Editor Information

  1. 2

    Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK

  2. 3

    Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA

  3. 4

    Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia

  4. 5

    Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine

Author Information

  1. Department of Medicine II, University of Freiburg, Freiburg, Germany

Publication History

  1. Published Online: 26 JUL 2013

ISBN Information

Print ISBN: 9780470672952

Online ISBN: 9781118637272

SEARCH

Keywords:

  • hepatitis C virus (HCV);
  • hepatocellular carcinoma (HCC);
  • chronic hepatitis;
  • viral life cycle;
  • epidemiology;
  • antiviral therapy

Summary

Hepatitis C virus infection is one of the major causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The genetic structure, genomic organization, and molecular biology of HCV, including the viral life cycle, as well the epidemiology, transmission, and natural course of HCV infection, have been studied in great detail. The continuous improvement of antiviral therapy and the most recent advances suggest that an effective treatment of most patients with chronic HCV infection may become reality in the near future.